Shots:
- Bayer has reported the P-III (PEACE-3) trial assessing Xofigo (radium-223 dichloride; 55kBq/kg, IV, QM for 6 cycles) + enzalutamide (160mg, PO, QD) vs enzalutamide in asymptomatic or mildly symptomatic pts (Brief Pain Inventory score <4) with mCRPC & ≥2 bone metastases
- Trial showed improved OS (2EP), with a 24% reduction in death risk & mOS of 38.2 vs 32.6mos., building on prior results of improved rPFS (1EP; 19.4 vs 16.4mos.)
- PEACE-3 results will be presented at the ASCO GU 2026 & published simultaneously in Annals of Oncology, plus updated rPFS results will also be reported
Ref: Businesswire | Image: Bayer | Press Release
Related News: Bayer Reports P-III (OCEANIC-STROKE) Trial Data on Asundexian for Secondary Stroke Prevention
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
